17.90
0.17 (0.96%)
| Previous Close | 17.73 |
| Open | 17.88 |
| Volume | 526,737 |
| Avg. Volume (3M) | 433,737 |
| Market Cap | 907,036,544 |
| Price / Earnings (TTM) | 31.40 |
| Price / Earnings (Forward) | 13.44 |
| Price / Sales | 12.78 |
| Price / Book | 4.42 |
| 52 Weeks Range | |
| Earnings Date | 10 Nov 2025 |
| Profit Margin | -89.38% |
| Operating Margin (TTM) | -93.80% |
| Diluted EPS (TTM) | -1.18 |
| Quarterly Revenue Growth (YOY) | 6.10% |
| Total Debt/Equity (MRQ) | 29.01% |
| Current Ratio (MRQ) | 4.77 |
| Operating Cash Flow (TTM) | 32.53 M |
| Levered Free Cash Flow (TTM) | 4.64 M |
| Return on Assets (TTM) | -7.98% |
| Return on Equity (TTM) | -31.46% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Theravance Biopharma, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | -4.0 |
| Price Volatility | -4.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.50 |
|
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 4.48% |
| % Held by Institutions | 91.75% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 40.00 (BTIG, 123.46%) | Buy |
| Median | 28.00 (56.43%) | |
| Low | 20.00 (HC Wainwright & Co., 11.73%) | Buy |
| Average | 29.33 (63.86%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 17.59 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 26 Nov 2025 | 40.00 (123.46%) | Buy | 19.96 |
| HC Wainwright & Co. | 11 Nov 2025 | 20.00 (11.73%) | Buy | 18.50 |
| B. Riley Securities | 12 Sep 2025 | 28.00 (56.42%) | Buy | 14.30 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| FARNUM RHONDA | - | 17.90 | -9,060 | -162,174 |
| GRIMAUD BRETT A. | - | 17.90 | -19,024 | -340,530 |
| MILLER AINE | - | 17.90 | -6,989 | -125,103 |
| SAWAF AZIZ | - | 17.90 | -18,627 | -333,423 |
| WINNINGHAM RICK E | 17.73 | 17.82 | -56,817 | -1,017,024 |
| Aggregate Net Quantity | -110,517 | |||
| Aggregate Net Value ($) | -1,978,254 | |||
| Aggregate Avg. Buy ($) | 17.73 | |||
| Aggregate Avg. Sell ($) | 17.87 | |||
| Insider Range ($) | ||||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| WINNINGHAM RICK E | Officer | 20 Nov 2025 | Disposed (-) | 56,817 | 17.90 | 1,017,024 |
| FARNUM RHONDA | Officer | 20 Nov 2025 | Disposed (-) | 9,060 | 17.90 | 162,174 |
| GRIMAUD BRETT A. | Officer | 20 Nov 2025 | Disposed (-) | 19,024 | 17.90 | 340,530 |
| MILLER AINE | Officer | 20 Nov 2025 | Disposed (-) | 6,989 | 17.90 | 125,103 |
| SAWAF AZIZ | Officer | 20 Nov 2025 | Disposed (-) | 18,627 | 17.90 | 333,423 |
| WINNINGHAM RICK E | Officer | 19 Nov 2025 | Disposed (-) | 9,900 | 17.73 | 175,527 |
| WINNINGHAM RICK E | Officer | 19 Nov 2025 | Acquired (+) | 9,900 | 17.73 | 175,527 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |